The CD58:CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity
P. Ho, J. C. Melms, M. Rogava, C. J. Frangieh, S. B. Shah, Z. Walsh, O. Kyrysyuk, A. D. Amin, L. Caprio, B. T. Fullerton, R. Soni, C. R. Ager, J. Biermann, Y. Wang, M. Mu, , B. Izar
The paper identifies the CD58:CD2 axis as co-regulated with PD-L1 via CMTM6 and shows its role in anti-tumor immunity, proposing therapeutic strategies to enhance immunotherapy.
bioRxiv · Mar 21, 2022 · PreprintCancer Biology